Karolinska Development (KDEV.ST) Stock Analysis & AI Equity Report
Karolinska Development (KDEV.ST) overview
Karolinska Development (KDEV.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Karolinska Development reported revenue of SEK 1.8m and operating profit of SEK -9.2m; the year-end share price was 0.95 SEK and market capitalisation was SEK 257m. Karolinska Development is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Karolinska Development's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About Karolinska Development
Karolinska Development is a Nordic life sciences investment company focused on identifying medical innovations in the region and building companies around them. It invests in the creation and growth of portfolio companies developing treatments and other health-related products, and supports them through development, financing, commercialization, licensing, divestments and possible listings.
Generate the Karolinska Development report
Karolinska Development is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Karolinska Development and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.